UK - GlaxoSmithKline is to make substantial changes to its board of executives following sustained pressure from pension fund investors.
The NAPF and the Association of British Insurers have been staunch critics of GSK’s remuneration policies – principally in relation to its chief executive officer Jean-Pierre Garnier, who was looki...
To continue reading this article...
Join Professional Pensions
Become a Professional Pensions Lite Member today
In just a few clicks you can start your free Professional Pensions Lite membership for 12 months, providing you access to:
- Three complimentary articles per month covering the latest real-time news, analysis and opinion from the industry
- Receive important and breaking news stories via our two daily news alerts
- Hear from industry experts and other forward-thinking leaders
Are you a trustee, investment consultant or in-house pension and benefit scheme professional? You can apply for full complimentary access here
